With EMT and rapid cytoskeleton reorganization being a staple cell event in the cancer context, developing a palette of crucial hubs within the HSP interactome as a target for multi-faceted inhibitors or SiRNA therapy may be a suitable strategy for impairing tumor progression. The gene discussed is HSP90B2P; the disease is cancer.